Navigation Links
Signalife Board Approves Merger
Date:7/11/2008

LOS ANGELES and LONDON, July 11 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) announced that it has received board approval to proceed with its previously-announced merger or similar business combination with Heart One Global Research, and that a specially-formed committee has been appointed to proceed with due diligence and other matters incident to completion of the transaction. As presently contemplated, a new parent company will be established by Signalife which will simultaneously acquire the businesses of Heart One and Signalife pursuant to concurrent mergers and exchange of shares. It is anticipated that the respective businesses of Signalife and Heart One will be operated in two separate wholly-owned subsidiaries, with the subsidiary holding Signalife's current business to be managed by Signalife's current management team, and the subsidiary holding Heart One's current business to be managed by Heart One's current management team.

Under the merger agreement, all shareholders of both Signalife and Heart One Global Research must physically deliver their share certificates to an independent third party tabulator. After the merger is effected, Signalife shareholders will own 94% of the surviving company. Signalife will be announcing certain distribution and financing transactions in the upcoming weeks. Signalife shall also endeavor to follow up with short market reports on a periodic basis to track the status of these transactions and the developments that have occurred. The public is also requested to view Signalife's website in the upcoming days to track the development of this business combination.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com. Clear Data. Trusted Results.

About Heart One Global Research

Heart One Global Research is the holding company for a number of assets, including various heart management and distribution arms worldwide and also including the renowned Health One Global, Ltd. (http://www.healthoneglobal.com). The latter subsidiary is the London-based international developer and distributor of information technologies that are clinically focused, mature, stable, robust, comprehensive, flexible, portable, and standards-based electronic health record solutions.

These technologies are available in Windows, Internet and USB Drive versions that can share a common record server giving maximum flexibility in implementation.

The technologies are used by about 3,000 healthcare professionals in 8 countries and in 4 languages. They have a 20-year history of continuous R&D evolution and refinement through long experience with several thousand physicians in supporting their daily delivery of healthcare in an unusually wide variety of clinical specialties, environments and organizations in multiple countries.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause the companies' actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating the companies' technology procure market acceptance for these products, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating the technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the devices, inability to obtain physician, patient or insurance acceptance of or for heart monitoring and other biomedical incorporating of the technologies, and the unavailability of financing to complete management's plans and objectives and the aforementioned merger agreement and its progeny, including the development of heart monitoring and other biomedical and information solutions incorporating the companies' technologies. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Announces AFL Joins NIH Education Program
2. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
3. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
4. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
5. Signalife Announces Webcast
6. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
7. Signalife Sees Accretive Purchase and Financial Commitments
8. Signalife Wins Second Frost & Sullivan Technology Award
9. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
10. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
11. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
Breaking Biology News(10 mins):